Neuronal and glial cell type-specific promoters within adenovirus recombinants restrict the expression of the apoptosis-inducing molecule pas ligand to predetermined brain cell types, and abolish peripheral liver toxicity

Journal of General Virology

Volumn 80, Issue 3, 1999, Pages 571-583

  Morelli, Adrian E ^a,b   Larregina, Adriana T ^a,b   Smith Arica, Joseph ^a   Dewey, Ricardo A ^a   Southgate, Thomas D ^a   Ambar, Benjamin ^c   Fontana, Adriano ^c   Castro, Maria G ^a   Lowenstein, Pedro R ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b Biomedical Science Tower ^*  (United States)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FAS LIGAND; GLIAL FIBRILLARY ACIDIC PROTEIN; NEURON SPECIFIC ENOLASE; VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; APOPTOSIS; ARTICLE; ASTROCYTE; BRAIN CELL; CELL LINE; CELL TYPE; EPITHELIUM CELL; FIBROBLAST; GENE EXPRESSION; GENE THERAPY; GLIA CELL; GRAFT REJECTION; HUMAN; HUMAN CYTOMEGALOVIRUS; LIVER CELL; LIVER TOXICITY; MOUSE; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROMOTER REGION; RAT; TRANSGENE; TUMOR; VIRUS RECOMBINANT;

EID: 0033032347     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/0022-1317-80-3-571     Document Type: Article

References (76)

1. Allison, J., Georgiou, H., Strasser, A. & Vaux, D. (1997). Transgenic expression of CD95 ligand on islet β cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proceedings of the National Academy of Sciences, USA 94, 3943-3947.
2. Andersen, J., Garber, D., Meaney, C. & Breakefield, X. (1992). Gene transfer into mammalian central nervous system using herpes-virus vectors. Extended expression of bacterial lacZ in neurons using the neuron specific enolase promoter. Human Gene Therapy 3, 487-499.
3. Andersen, J., Frim, D., Isacson, O. & Breakefield, X. (1993). Herpesvirus-mediated gene delivery into the rat brain: specificity and efficiency of the neuron-specific enolase promoter. Cellular and Molecular Neurobiology 13, 503-515.
4. Bellgrau, D., Gold, D., Selawry, H., Moore, J., Franzusoff, A. & Duke, R. (1995). A role for CD95 ligand in preventing graft rejection. Nature 377, 630-632.
5. Bonetti, B., Pohl, J., Gao, Y. & Raine, C. (1997). Cell death during autoimmune demyelination: effector but not target cells are eliminated by apoptosis. Journal of Immunology 159, 5733-5741.
6. Boyd, J., Malstrom, S., Subramanian, T., Venkatesh, L., Schaeper, U., Elangovan, B., Dsaeipper, C. & Chinnadurai, G. (1994). Adenovirus E1B 19 kDa and Bcl-2 proteins interact with a common set of cellular proteins. Cell 79, 341-351.
7. Brenner, M., Kisseberth, W., Su, Y., Besnard, F. & Messing, A. (1994). GFAP promoter directs astrocyte-specific expression in transgenic mice. Journal of Neuroscience 14, 1030-1037.
8. Byrnes, A., MacLaren, R. & Charlton, H. (1996). Immunological instability of persistent adenovirus vectors in the brain: peripheral exposure to vector leads to renewed inflammation, reduced gene expression and demyelination. Journal of Neuroscience 16, 3045-3055.
9. Castro, M. G., Goya, R. G., Sosa, Y. E., Rowe, J., Larregina, A., Morelli, A. & Lowenstein, P. R. (1997). Expression of transgenes in normal and neoplastic anterior pituitary cells using recombinant adenoviruses : long term expression, cell cycle dependency, and effects on hormone secretion. Endocrinology 138, 2184-2194.
10. Forss-Peter, S., Danielson, P., Catsicas, S., Battenberg, E., Price, J., Hurenberg, M. & Sutcliffe, J. (1990). Transgenic mice expressing β-galactosidase in mature neurons under neuron specific enolase promoter control. Neuron 5, 187-197.
11. French, L., Hahne, M., Viard, I., Radlgruber, G., Zanone, R., Becker, K., Muller, Ch. & Tschopp, J. (1996). Fas and fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. Journal of Cell Biology 133, 335-343.
12. Galle, P., Hofmann, W., Walczak, H., Schaller, H., Otto, G., Stremmel, W., Krammer, P. & Runkel, L. (1995). Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. Journal of Experimental Medicine 182, 1223-1230.
13. Geddes, B., Harding, T., Hughes, D., Byrnes, A., Lightman, S., Conde, G. & Uney, J. (1996). Persistent transgene expression in the hypothalamus following extereotaxic delivery of a recombinant adenovirus-suppression on the immune response with cyclosporine. Endocrinology 137, 5166-5169.
14. Geddes, B., Harding, T., Lightman, S. & Uney, J. (1997). Long-term gene therapy in the CNS: reversal of hypothalamic diabetes insipidus in the Brattleboro rat by using an adenovirus expressing arginine vasopressin. Nature Medicine 3, 1402-1404.
15. Green, D. & Ware, C. (1997). Fas-ligand: privilege and peril. Proceedings of the National Academy of Sciences, USA 94, 5986-5990.
16. Griffith, T. & Ferguson, T. (1997). The role of FasL-induced apoptosis in immune privilege. Immunology Today 18, 240-244.
17. Griffith, T., Brunner, T., Fletcher, S., Green, D. & Ferguson, T. (1996). Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270, 1189-1192.
18. Hahne, M., Rimoldi, D., Schrotter, M., Romero, P., Schreier, M., French, L., Schneider, P., Bornand, T., Fontana, A., Lienard, D., Cerottini, J. C. & Tschopp, J. (1996). Melanoma cell expression of Fas (APO-1/CD95) ligand: implications for tumour immune escape. Science 274, 1363-1366.
19. Hashimoto, M., Aruga, J., Hosoya, Y., Kenegae, Y., Saito, I. & Mikoshiba, K. (1996). A neural cell-type-specific expression system using recombinant adenovirus vectors. Human Gene Therapy 7, 149-158.
20. Hoffman, M., Zheng, C., Baum, B., O'Connell, B. & Kleinman, H. (1997). Identification of components in Matrigel involved in salivary gland acinar cell differentiation using an adenovirus vector with an acinar cell specific promoter luciferase reporter. Matrix Biology 16, 72.
21. Imler, J., Dupuit, F., Charteir, C., Accart, N., Dieterle, A., Schultz, H., Fuchelle, E. & Pavirani, A. (1996). Targeting cell-specific gene-expression with an adenovirus vector containing the lacZ gene under the control of the CFTR promoter. Gene Therapy 3, 49-58.
22. Kajiwara, K., Byrnes, A., Charlton, H., Wood, M. & Wood, K. (1997). Immune responses to adenoviral vectors during gene transfer in the brain. Human Gene Therapy 8, 243-265.
23. Kanai, F., Shiratori, Y., Yoshida, Y., Wakimoto, H., Hamada, H., Kanegae, Y., Saito, I., Nakabayashi, H., Tamaoki, T., Tanaka, T., Lan, K., Kato, N. & Shina, S. (1996). Gene-therapy for alpha-fetoprotein producing human hepatoma cells by adenovirus-mediated transfer of the herpes-simplex virus thymidine kinase gene. Hepatology 23, 1359-1368.
24. Kang, A., Schneider, D., Lin, Z., Hanahan, D., Dicher, D., Stock, P. & Baekkekov, S. (1997). Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nature Medicine 3, 738-743.
25. Kaplitt, M. G., Kwong, A. D., Kleopoulos, S. P., Mobbs, C. V., Rabkin, S. D. & Pfaff, D. W. (1994). Preproenkephalin promoter yields region-specific and long term expression in adult brain after direct in vivo gene transfer via a defective herpes simplex viral vector. Proceedings of the National Academy of Sciences, USA 91, 8979-8983.
26. Kay, M., Meuse, L., Gown, A., Linsley, P., Hollenbaugh, D., Aruffo, A., Ochs, H. & Wilson, C. (1997). Transient immunomodulation with anti-CD40 ligand antibody and CTLA4 Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver. Proceedings of the National Academy of Sciences, USA 94, 4686-4691.
27. Kayagaki, N., Kawasaki, A., Ebata, T., Ohmoto, H., Ikeda, S., Inoue, S., Yoshino, K., Okumura, K. & Yagita, H. (1995). Metalloproteinase-mediated release of human Fas ligand. Journal of Experimental Medicine 182, 1777-1783.
28. Kiener, P., Davis, P., Starling, G., Mehlin, C., Klebanoff, S., Ledbetter, J. & Liles, W. (1997). Differential induction of apoptosis by Fas-Fas ligand interactions in human monocytes and macrophages. Journal of Experimental Medicine 185, 1511-1516.
29. Kim, S., Lin, H., Barr, E., Chu, L., Leiden, J. & Parmack, M. (1997). Transcriptional targeting of replication-defective adenovirus transgene expression to smooth muscle cells in vivo. Journal of Clinical Investigation 100, 1006-1014.
30. Ko, S., Cheon, J., Kao, C., Gotoh, A., Shirakawa, T., Sikes, R., Karsenty, G. & Chung, L. (1996). Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma in experimental models. Cancer Research 56, 4614-4619.
31. Koppi, T., Toughbement, T., Lewinsohn, D., Lynch, D. & Alderson, M. (1997). CD40 ligand inhibits Fas/CD95-mediated apoptosis of human blood-derived dendritic cells. European Journal of Immunology 27, 3161-3165.
32. Korbutt, G., Elliott, J. & Rajotte, R. (1997). Cotransplantation of allogeneic islets with allogeneic testicular cell aggregates allows long-term graft survival without systemic immunosuppression. Diabetes 46, 317-322.
33. Lan, K., Kanai, F., Shiratori, Y., Ohashi, M., Tanaka, T., Okudaira, T., Yoshida, Y., Hamada, H. & Omata, M. (1997). In vivo selective gene expression and therapy mediated by adenoviral vectors for human carcinoembryonic antigen-producing gastric carcinoma. Cancer Research 57, 4279-4284.
34. Larregina, A., Morelli, A., Dewey, R., Castro, M., Fontana, A. & Lowenstein, P. (1998). FasL induces Fas/Apo1-mediated apoptosis in human embryonic kidney 293 cells routinely used to generate E1-deleted adenoviral vectors. Gene Therapy 5, 563-568.
35. Lau, H., Yu, M., Fontana, A. & Stoeckert, Ch. (1996). Prevention of islets allograft rejection with engineered myoblast expressing FasL in mice. Science 273, 109-112.
36. Lin, R. & Matesic, D. (1994). Immunohistochemical demonstration of neuron-specific enolase and microrubule-associated protein 2 in reactive astrocytes after injury in the adult forebrain. Neuroscience 60, 11-16.
37. Lowenstein, P. R., Morrison, E. E., Bain, D., Shering, A. F., Banting, G., Douglas, P. & Castro, M. G. (1994). Polarized distribution of the trans-Golgi network marker TGN38 during the in vitro development of neocortical neurons: effects of nocodazole and brefeldin A. European Journal of Neuroscience 6, 1453-1465.
38. Lowenstein, P. R., Shering, A. F., Morrison, E., Tomasec, P., Bain, D., Jacob, T. J. C., Wu, J., Prescott, A. & Castro, M. G. (1995). Synaptogenesis and distribution of presynaptic axonal varicosities in low density primary cultures of neocortex: an immunocytochemical study utilizing synaptic vesicle-specific antibodies, and an electrophysiological examination utilizing whole cell recording. Journal of Neurocytology 24, 301-317.
39. Malipiero, U., Frei, K., Spanaus, K., Agresti, C., Lassmann, H., Hahne, M., Tschopp, J., Eugster, H. & Fontana, A. (1997). Myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis is chronic/relapsing in perforin knockout mice, but monophasic in Fas- and Fas ligand-deficient lpr and gld mice. European Journal of Immunology 12, 3151-3160.
40. Miura, M., Tamura, T. & Mikoshiba, K. (1990). Cell-specific expression of the mouse glial fibrillary acidic protein gene : identification of the cis- and trans-acting promoter elements for astrocyte-specific expression. Journal of Neurochemistry 55, 1180-1188.
41. Morishita, K., Johnson, D. & Williams, L. (1995). A novel promoter for vascular endothelial growth-factor receptor (flt-1) that confers endothelial-specific gene-expression. Journal of Biological Chemistry 270, 27948-27953.
42. Muruve, D., Nicolson, A., Manfro, R., Strom, T., Sukhatme, V. & Libermann, T. (1997). Adenovirus-mediated expression of Fas ligand induces hepatic apoptosis after systemic administration and apoptosis of ex vivo-infected pancreatic islet allografts and isografts. Human Gene Therapy 8, 955-963.
43. Nicoletti, I., Migliorati, G., Pagliacci, M., Grignani, F. & Riccardi, C. (1991). A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. Journal of Immunological Methods 139, 271-279.
44. Niehans, G., Brunner, T., Frizelle, S. P., Liston, J., Salerno, C. T., Knapp, D. J., Green, D. R. & Kratzke, R. A. (1997). Human lung carcinoma express Fas ligand. Cancer Research 57, 1007-1012.
45. Nishimura, T., Akiyama, H., Yonehara, S., Kondo, H., Ikeda, K., Kato, M., Iseki, E. & Kosaka, K. (1995). Fas antigen expression in brains of patients with Alzheimer-type dementia. Brain Research 695, 137-145.
46. O'Connell, J., O'Sullivan, G., Collings, J. & Shanahan, F. (1996). The Fas counterattack: Fas-mediated T cell killing by colon cancer expressing Fas ligand. Journal of Experimental Medicine 184, 1075-1082.
47. Ogasawara, J., Watanabe-Fukunaga, R., Adachi, M., Matsuzawa, A., Kasugai, T., Kitamura, Y., Itoh, N., Suda, T. & Nagata, S. (1993). Lethal effect of the anti-fas antibody in mice. Nature 364, 806-809.
48. Osborne, B. A. (1996). Apoptosis and the maintenance of homeostasis in the immune system. Current Opinion in Immunology 8, 245-254.
49. Peel, A., Zolotukhin, S., Schrimsher, G., Muzyczka, N. & Reier, P. (1997). Efficient transduction of green fluorescent protein in spinal cord neurons using adeno-associated virus vectors containing cell type-specific promoters. Gene Therapy 4, 16-24.
50. Rensing-Ehl, A., Rei, K., Flury, R., Matiba, B., Mariani, S., Weller, M., Aebischer, P., Krammer, P. & Fontana, A. (1995). Local Apo-1/Fas (CD95) ligand-mediated tumor cell killing in vivo. European Journal of Immunology 25, 2253-2258.
51. Rensing-Ehl, A., Malipiero, U., Irmler, M., Tschopp, J., Constam, D. & Fontana, A. (1996). Neurons induced to express major histocompatibility complex class I antigen are killed via the perforin and not the Fas (APO-1/CD95) pathway. European Journal of Immunology 26, 2271-2274.
52. Rodriguez, R., Schuur, E., Lim, H., Henderson, G., Simons, J. & Henderson, D. (1997). Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Research 13, 1559-1563.
53. Roemer, K., Johnson, P. & Friedmann, T. (1995). Transduction of foreign regulatory sequences by a replication-defective herpes simplex virus type 1: the rat neuron-specific enolase promoter. Virus Research 35, 781-789.
54. Rothmann, T., Katus, H., Hartong, R., Perricaudet, M. & Franz, W. (1996). Heart muscle-specific gene-expression using replication-defective recombinant adenovirus. Gene Therapy 3, 919-926.
55. Saas, P., Walker, P. R., Hahne, M., Quiquerez, A. L., Schnuriger, V., Perrin, G., French, L., Van Meir, E. G., de Tribolet, N., Tschopp, J. & Dietrich, P. Y. (1997). Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? Journal of Clinical Investigation 99, 1173-1178.
56. Samaniego, L., Wu, N. & DeLuca, N. (1997). The herpes simplex virus immediate-early protein ICP0 affects transcription from the viral genome and infected-cell survival in the absence of ICP4 and ICP27. Journal of Virology 71, 4614-4625.
57. Samaniego, L., Neiderhiser, L. & DeLuca, N. (1998). Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins. Journal of Virology 72, 3307-3320.
58. Sanberg, P., Borlongan, C., Saporta, S. & Cameron, D. (1996). Testis-derived sertoli cells survive and provide localized immunoprotection for xenografts in rat brain. Nature Biotechnology 14, 1692-1695.
59. Sandig, V., Loser, P., Lieber, A., Kay, M. & Strauss, M. (1996). HBV-derived promoters direct liver-specific expression of an adenovirally transduced LDL receptor gene. Gene Therapy 3, 1002-1009.
60. Sata, M., Perlman, H., Muruve, D. A., Silver, M., Ikebe, M., Libermann, T. A., Oettgen, P. & Walsh, K. (1998). Fas ligand gene transfer to the vessel wall inhibits neointima formation and overrides the adenovirus-mediated T cell response. Proceedings of the National Academy of Sciences, USA 95, 1213-1217.
61. Schneider, P., Holler, N., Bodmer, J., Hahna, M., Frei, K., Fontana, A. & Tschopp, J. (1998). Conversion of membrane-bound Fas (CD95) ligand to its soluble form is associated with down regulation of its proapoptotic activity and loss of liver toxicity. Journal of Experimental Medicine 187, 1205-1213.
62. Seino, K., Kayagaki, N., Okumura, K. & Yagita, H. (1997). Antitumor effect of locally produced CD95 ligand. Nature Medicine 3, 165-170.
63. Shering, A. F., Bain, D., Stewart, K., Epstein, A. L., Castro, M. G., Wilkinson, G. W. G. & Lowenstein, P. R. (1997). Cell type-specific expression in brain cell cultures from a short human cytomegalovirus major immediate early promoter depends on whether it is inserted into herpesvirus or adenovirus vectors. Journal of General Virology 78, 445-459.
64. Shimizu, M., Yoshimoto, T., Nagata, S. & Matsuzawa, A. (1996). A trial to kill tumor cells through Fas (CD95)-mediated apoptosis in vivo. Biochemical and Biophysical Research Communication 228, 375-379.
65. Siders, W., Halloran, P. & Fenton, R. (1996). Transcriptional targeting of recombinant adenoviruses to human and murine melanoma cells. Cancer Research 56, 5638-5646.
66. Strand, S., Hoffmann, W., Hug, H., Muller, M., Otto, G., Strand, D., Mariani, S., Stremmel, W., Krammer, P. & Galle, P. (1996). Lymphocyte apoptosis induced by CD95 (APO-1/FAS) ligand: implications for tumour immune escape. Nature Medicine 2, 1361-1366.
67. Suda, T. & Nagata, S. (1994). Purification and characterization of the Fas-ligand that induces apoptosis. Journal of Experimental Medicine 179, 873-879.
68. Suda, T., Takahashi, T., Golstein, P. & Nagata, S. (1993). Molecular cloning and expression of the FAS ligand, a novel member of tumour necrosis factor family. Cell 75, 1169-1178.
69. Tollefson, A. E., Hermiston, T. W., Lichtenstein, D. L., Colle, C. F., Tripp, R. A., Dimitrov, T., Toth, K., Wells, C. E., Doherty, P. C. & Wold, W. S. M. (1998). Forced degradation of Fas inhibits apoptosis in adenovirus-infected cells. Nature 392, 726-730.
70. van Parijs, L. & Abbas, A. (1996). Role of Fas-mediated cell death in the regulation of immune responses. Current Opinion in Immunology 8, 355-361.
71. Vaux, D. (1995). Ways around rejection. Nature 377, 576-577.
72. Weller, M., Frei, K., Groscurth, P., Krammer, P. H., Yonekawa, Y. & Fontana, A. (1994). Anti-Fas Apo-1 antibody mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines. Journal of Clinical Investigation 94, 954-964.
73. Wilkinson, G. W. G. & Akrigg, A. (1991). Constitutive and enhanced expression from the CMV major IE-promoter in a defective adenovirus vector. Nucleic Acids Research 20, 2233-2239.
74. Wrann, M., Bodmer, S., Demartin, R., Siepl, C., Hoferwarbinek, R., Frei, K., Hofer, E. & Fontana, A. (1987). T-cell supressor factor from human glioblastoma cells is a 12-5 kD protein closely related to transforming growth factor beta. EMBO Journal 6, 1633-1636.
75. Zhang, H., Yang, Y., Horton, J., Samoilova, E., Judge, T., Turka, L., Wilson, J. & Chen, Y. (1997). Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer. Journal of Clinical Investigation 100, 1951-1957.
76. Zhang, H., Bilbao, G., Zhou, T., Contreras, J., Gomez-Navarro, J., Feng, M., Saito, I., Mountz, J. & Curiel, D. (1998). Application of a Fas ligand encoding a recombinant adenovirus vector for prolongation of transgene expression. Journal of Virology 72, 2483-2490.